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OBJECTIVE—The prognostic signiﬁcance of diabetic retinopathy (DR) for death and cardio-
vascular (CV) outcomes is debated. We investigated the association of DR with all-cause mor-
tality and CV events in patients with diabetes by a systematic review and meta-analysis.
RESEARCH DESIGN AND METHODS—The electronic databases Medline and Embase
were searched for cohort studies that evaluated DR in type 2 or type 1 diabetic patients and
reported total mortality and/or fatal and nonfatal CV events, including myocardial infarction,
angina pectoris, coronary artery bypass graft, ischemic changes on a conventional 12-lead elec-
trocardiogram, transient ischemic attack, nonfatal stroke, or lower leg amputation. Data extrac-
tion was performed by two reviewers independently. Pooled effect estimates were obtained by
using random-effects meta-analysis.
RESULTS—Theanalysisincluded20studiesthatfulﬁlledtheinclusioncriteria,providingdata
from19,234 patients.In patientswith type 2diabetes(n=14,896),thepresenceof any degreeof
DR increased the chance for all-cause mortality and/or CV events by 2.34 (95% CI 1.96–2.80)
compared with patients without DR. In patients with type 1 diabetes (n = 4,438), the corre-
sponding odds ratio was 4.10 (1.50–11.18). These associations remained after adjusting for
traditional CV risk factors. DR was also predictive of all-cause mortality in type 2 diabetes (odds
ratio 2.41 [1.87–3.10]) and type 1 diabetes (3.65 [1.05–12.66]).
CONCLUSIONS—The presence of DR was associated with an increased risk of all-cause
mortality and CV events in both type 2 and type 1 diabetic patients.
Diabetes Care 34:1238–1244, 2011
D
iabetic retinopathy (DR) is a com-
mon chronic microvascular diabe-
tes complication. Approximately
29% of U.S. adults with type 2 diabetes
have DR (1), whereas DR will develop in
95% of type 1 diabetic individuals during
their lifetime (2). DR has been associated
with increased all-cause and cardiovascu-
lar (CV) mortality risk in both type 2 and
type 1 diabetes (3–7). Associations with
DR have been more extensively evaluated
in type 2 diabetes, whereas studies in
type 1 diabetes are scarce.
Considering these data, identiﬁcation
of DR could possibly add to the diabetic
patient’sC Vr i s ks t r a t i ﬁcation. Further-
more, the fundus examination is inex-
pensive and is routinely performed for
the screening of chronic diabetes compli-
cations. Therefore, it is worthwhile to
comprehensively review data on the pre-
dictive role of DR. The aim of the current
study was to investigate the association
of DR with all-cause mortality and CV
events (fatal and nonfatal) in type 2 and
type 1 diabetic patients by a systematic
review and meta-analysis of cohort
studies.
RESEARCH DESIGN AND
METHODS
Data sources and searches
The electronic databases (beginning in
1950 until July 2010) Medline and
Embase were searched for the medical
subject headings (MeSH) “Diabetic Reti-
nopathy” and“mortality” or “cardiovascu-
lar disease” to identify observational
studies that report the incidence of all-
cause mortality, and fatal and nonfatal
CV events in diabetic patients whose DR
was evaluated (regardless of the language).
Study selection
Studies were considered eligible for in-
clusion if they fulﬁlled the following in-
clusion criteria:
1. presented original data of prospective,
observational studies;
2. evaluated the presence of DR, deﬁned
as any degree and/or severity accord-
ingtowell-validatedscales,suchasthe
Early Treatment Diabetic Retinopathy
Study severity scale (8), in type 2 or
type 1 diabetic patients; and
3. reported all-cause mortality and/or
fatal or nonfatal CV events.
When studies reported more than
one outcome separately, only all-cause
mortality data were included. Fatal and
nonfatal CV events were deﬁned as a
positive medical history of a CV event,
including death due to CV disease and/or
any of the following: myocardial infarc-
tion, angina pectoris, coronary artery
bypass graft, ischemic changes on a con-
ventional 12-lead electrocardiogram,
transient ischemic attack, nonfatal stroke,
or lower leg amputation.
Data extraction and quality
assessment
Data were extracted independently by
twoinvestigatorswithanagreementvalue
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META-ANALYSISof k = 96%. Disagreements were resolved
by a third author.
Extracted data included the clinical
characteristics of participants, study de-
sign, and follow-up, assessment of DR,
and the number of participants who had
the outcome according to DR status.
Numeric data reported in the articles
were used. In the few studies not report-
ing these data, risk estimates were calcu-
lated from the survival curves.
The Newcastle-Ottawa Scale for as-
sessing quality of nonrandomized studies
in meta-analysis was used (9).
Data synthesis and analysis
An overall odds ratio (OR) was calculated
to assess the predictive value of DR for
all-causemortalityand/orCVevents(com-
posite outcome). DR was evaluated either
as “any degree” or “advanced DR” com-
pared with the group without DR in anal-
yses stratiﬁed by type of diabetes (type 1
and type 2). Advanced DR was deﬁned as
the most severe category of DR described:
proliferative DR, severe nonproliferative
DR,sight-threateningDR,oranycombina-
tion of these categories.
The Cochran x
2 and the I
2 tests were
used to evaluate heterogeneity among
studies and a threshold value of P =0 . 1 0
was considered signiﬁcant (10). The risk
estimates were obtained with random-
effects meta-analysis because a signiﬁcant
heterogeneity was found among studies
in preliminary models.
Meta-regression analyses were used
to investigate potential sources of hetero-
geneity. The factors investigated were age,
malesex,proportionofsmokers,A1Ctest,
and follow-up period (previously chosen
based on their biologic relevance). In a
meta-regressionanalysisoftype1diabetes,
only follow-up and A1C tests were in-
cluded because the number of studies
limited a broader evaluation of potential
confounders. A sensitivity analysis includ-
ingonlyall-causemortalityasanendpoint
was performed to minimize the inﬂuence
ofCVriskfactorsaspotentialconfounders.
Receiver operating characteristic
(ROC) curves were constructed to obtain
the pooled estimates of sensitivity and
speciﬁcity of DR for the development of
outcomes. The average likelihood ratio of
the positive and negative test result was
calculated. For practical clinical purposes,
the post-test probability of the outcome
was estimated using the Bayes normo-
gram, considering the pretest probability
as the mean proportion of the event in the
included population (11).
The possibility of publication bias
was evaluated using a funnel plot of a
trial’s effect size against the SE. Funnel
plot asymmetry was evaluated by the
Begg and Egger tests. The trim-and-ﬁll
computation was used to estimate the ef-
fect of publication bias (12).
All statistical analyses were performed
using Stata 11.0 software (StataCorp,
College Station, TX).
RESULTS
Literature search results and study
characteristics
We identiﬁed 3,180 studies in the data-
base searches (Fig. 1). Among these stud-
ies, 3,149 were exclu d e db a s e do nt i t l e
and abstract, leaving 31 studies for fur-
ther evaluation. Of these, 11 studies
were excluded after full-text evaluation
(Supplementary Table 1). A total of 20
studies, comprising 19,234 patients, ful-
ﬁlled our inclusion criteria and were in-
cluded.
Table 1 summarizes the characteris-
tics of the included studies. A total of 17
studies with a mean follow-up of 8.95
years evaluated type 2 diabetic patients
(n = 14,896; mean age, 58.4 years) and
four studies with a mean follow-up of
12.37 years evaluated type 1 diabetic pa-
tients (n = 4,438; mean age, 32.7 years).
In accordance with the Newcastle-
Ottawa quality assessment scale for co-
hort studies, all studies achieved at least
six stars, indicating an overall good qual-
ity (Table 2). Funnel plots and the Egger
regression test suggested a borderline
signiﬁcant asymmetry in the analysis of
type 2 diabetes (P = 0.10). However, the
trim-and-ﬁll computation revealed that
there were no missing trials, indicating
that the publication bias did not interfere
with the interpretation of the results.
There were no publication biases in anal-
ysis of type 1 diabetes in both tests (P =
0.21).
DR and all-cause mortality
and/or CV events
Type 2 diabetes. In the pooled analysis
of the 17 included studies, the OR for all-
cause mortality and/or CV events of the
presence of DR was 2.34 (95% CI 1.96–
2.80) compared with patients without
DR (Fig.2A).Allbutthreestudiesreported
an increased risk for events. However, a
signiﬁcant heterogeneity among the indi-
vidual estimates was evident when the
magnitude of the association was evalu-
ated (I
2 = 62.7%, P , 0.001).
Figure 1—Flowdiagramshows theliteraturesearch to identifycohort studies thatevaluatedDR
and all-cause mortality and/or CV events (fatal and nonfatal) of diabetic patients.
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Diabetic retinopathy and mortalityThe overall sensitivity of any DR for
thecompositeoutcomewas43%(95%CI
36–50), and the speciﬁcity was 75% (71–
80). The positive likelihood ratio was
1.78 (1.57–2.00) and the negative likeli-
hood ratio was 0.75 (0.68–0.82). The
post-test probability of the composite
outcome for patients who had any degree
of DR was 34% considering a pretest
probability of 23% (Fig. 3A).
In an exploratory attempt to identify
the sources of heterogeneity among trials,
we undertook a meta-regression analysis
considering as covariates baseline age, pro-
portion of men, proportion of smokers,
A1C test, and follow-up. None of them
explained the among-studies variance
(overall P =0 . 8 0 ) .
The ORs for the composite outcome
were also adjusted for CV risk factors
(age, sex, diabetes duration, blood pres-
sure, smoking status, albuminuria, and
lipidproﬁle)in12oftheincludedstudies.
A meta-analysis was performed taking
these adjusted ORs into account, even
though these studies did not include the
same covariates. The presence of DR still
predicted events in this adjusted meta-
analysis (OR 1.61 [95% CI 1.32–1.90]).
When advanced DR was evaluated
(10 reports), the OR for all-cause mortal-
ity and/or CV events was 4.22 (95% CI
2.81–6.33) compared with patients
without retinopathy (I
2 =6 3 . 0 % ,P =
0.004). The overall sensitivity of ad-
vanced DR for the combined outcome
was 19% (13–28), and the speciﬁcity
was94%(91–96).Thepositivelikelihood
ratio was 3.64 (2.52–5.26) and the nega-
tive likelihood ratio was 0.84 (0.77–
0.92). The post-test probability of an
event occurring in an individual with ad-
vanced DR was 48% by using the Bayes
normogram and considering a pretest
probability of 23% (Fig. 3C).
Type 1 diabetes. In the pooled analysis
of four included studies, the OR for all-
cause mortality and/or CV events of any
DR was 4.10 (95% CI 1.50–11.18) com-
pared with individuals without retinopa-
thy (Fig. 2). A signiﬁcant heterogeneity
among trials was present (I
2 = 86.9%,
P , 0.001).
The overall sensitivity of any DR for
thecompositeoutcomewas70%(95%CI
30–93), and the speciﬁcity was 60% (29–
85).Thecorrespondingpositivelikelihood
ratio was 1.80 (1.20–2.70) and the nega-
tive likelihood ratio was 0.47 (0.22–1.04;
Fig. 3B). The post-test probability of an
event occurring in a patient with DR was
12% by using the Bayes normogram and
considering a pretest probability of 7.5%.
Inameta-regressionanalysisincluding
thefollow-upperiodandbaselineA1Ctest
as possible sources of heterogeneity, the
follow-up of the studies explained almost
100% of the differences among the stud-
ies. Therefore, a sensitive analysis includ-
ing only the three studies with follow-up
.10 years was performed, demonstrating
anORofDRforthecompositeoutcomeof
6.45 (95% CI 3.91–10.85) with heteroge-
neity of 0% (P = 0.90).
Three studies also presented an ad-
justed OR of the risk conferred by DR.
The presence of any DR still predicted
all-cause mortality and CV events when a
meta-analysis using these adjusted data
were performed (OR 1.58 [95% CI 1.33–
1.89]).
Three reports also included evalua-
tionofadvancedDR.TheORforall-cause
mortality and/or CV events of advanced
DR was 7.00 (95% CI 2.22–20.0) com-
pared with patients without DR (I
2 =
85.0%, P , 0.001). Because only three
studies were included in this analysis,
the ROC curve could not be constructed.
DR and all-cause mortality in type 2
and type 1 diabetes
In the sensitivity analyses evaluating only
the eight studies that reported data on
all-cause mortality, the presence of DR
i n c r e a s e dm o r et h a nt w o f o l dt h er i s kf o r
death (OR 2.41 [95% CI 1.87–3.10]) in
patients with type 2 diabetes. The risk for
death was also greater in patients with
type 1 diabetes and DR compared with
those without DR, considering three in-
cluded studies (OR 3.65 [1.05–12.66];
Fig. 2B).
CONCLUSIONS—Thesemeta-analyses
of cohort studies showed that the pres-
ence of any degree of DR or advanced DR
was associated with an increased risk for
all-cause mortality and CV events (fatal
and nonfatal) in both type 2 and type 1
diabetic patients. Data from the current
study show that funduscopy can be a
practical tool to identify patients who are
at increased risk for adverse outcomes,
as demonstrated by the inﬂuence of DR
in the post-test probability of having an
event.
Our literature search was extensive;
we tested for and found no evidence of
publication bias. The quality of original
studies was checked according to the
Newcastle scale statement and most of
the studies fulﬁlled all components. We
also are aware that publication bias and
the quality issues of individual studies
may still exist despite our best efforts to
conduct a comprehensive search and the
lack of statistical evidence of existence of
Table 2—Newcastle-Ottawa quality assessment scale for cohort studies
Study reference (author, year) Selection Comparability Outcome
Type 2 diabetes
Sasaki, 1989 (19) **** * ***
Hanis, 1993 (16) **** * ***
Miettinen, 1996 (7) *** * ***
Forsblom, 1998 (20) *** * ***
Klein, 1999 (4) **** * **
Kim, 2002 (21) *** * ***
Ono, 2002 (22) *** * ***
Rius Riu, 2003 (23) **** * ***
Gimeno-Orna, 2006 (24) *** * ***
Cheung, 2007 (25) **** * ***
Cheung, 2007 (26) **** * ***
Lövestam-Adrian, 2007 (27) *** * **
Juutilainen, 2007 (28) **** * ***
Tong, 2007 (29) *** * ***
Cheung, 2008 (30) **** * ***
Liew, 2009 (31) **** * ***
Gimeno-Orna, 2009 (32) *** * ***
Type 1 diabetes
Klein, 1999 (4) **** * **
Weis, 2001 (33) *** * ***
Torffvit, 2005 (34) **** * ***
Soedamah-Muthu, 2008 (5) **** * ***
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Kramer and Associatesbias. Another possible limitation is that
our adjusted meta-analyses undertaken
were not ideal because the authors of the
original studies used different statistical
models. However, we must take into ac-
count that the potential confounders
(covariates) were chosen in each original
studyaccording tosamplecharacteristics.
The development of DR has been
associated with known risk factors for
CV disease such as hypertension, hyper-
glycemia,andalbuminuria(2).Therefore,
the association of DR with CV events
would be expected, and one might think
that DR is just a marker of a worse clinical
status. However, in the meta-regression
analyses, CV confounders didnotexplain
the between-studies variance, suggesting
that theserisk factorsdonotfullyaccount
for the observed association. In parallel to
that, our results did not change when ad-
ditional meta-analyses were performed,
including only the studies where the risk
determined by DR was adjusted for possi-
ble confounders in both type 2 and type 1
diabetes.
An important aspect that should be
considered is that the therapeutic goals
in diabetes care have changed over time.
The intensiﬁcation of glycemic control in
patients with type 1 diabetes became
widespread after the publication of the
DiabetesControlandComplicationsTrial
studyin1993(13).Inpatientswithtype2
diabetes, a signiﬁcant reduction in LDL
cholesterol levels and blood pressure
were observed since 1990 (14). These is-
sues might have inﬂuenced mortality
rates as well as the effects of risk factors
in our meta-analysis because the timeline
of included studies ranged from the
1960sto2008.However,despitechanges
in goals to be achieved in patients with
diabetes, the mortality rate was compara-
ble during the periods of 1971 through
1986 and 1988 through 2000 (15). In
parallel to that, the timelines of included
studies all overlapped.
Highlighting the importance of DR
as a possible novel marker for events in
patients with diabetes is that DR was
strongly associated with all-cause mortal-
ity,beyonditsassociationwithCVevents.
In fact, CV disease was the cause of death
in less than 35% of individuals in most of
the included studies (4,16), suggesting
an additional mechanism by which the
presence of DR increases death. In this
sense,thepresence of autonomic neurop-
athy could be a possible link between DR
and CV events. Indeed, it was recently
demonstrated thatautonomousderegula-
tion could lead to alterations in blood
pressure and cardiac rhythm, which
were associated with DR (17,18).
In conclusion, the presence of DR
w a sa s s o c i a t e dw i t ha ni n c r e a s e dr i s k
for all-cause mortality and CV events in
both type 2 and type 1 diabetes. Further
studies are needed to understand the role
of the inclusion of DR in mortality pre-
dictionscoresaswellastounderstandthe
link between death/CV events and DR,
especially the all-cause mortality DR as-
sociation.
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